Does Dr. CHAIYAPORN BOONCHALERMVICHIAN have financial conflicts of interest?

Dr. CHAIYAPORN BOONCHALERMVICHIAN (MD) has received a total of $157 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $157 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. CHAIYAPORN BOONCHALERMVICHIAN?

According to CMS Open Payments data, Dr. CHAIYAPORN BOONCHALERMVICHIAN received funding from KITE PHARMA ($118), BAYER HEALTHCARE PHARMACEUTICALS ($23), and CUMBERLAND PHARMACEUTICALS ($16).

Does Dr. CHAIYAPORN BOONCHALERMVICHIAN receive research grants or speaking fees?

Dr. CHAIYAPORN BOONCHALERMVICHIAN has received $157 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. CHAIYAPORN BOONCHALERMVICHIAN

MDReal-Time Hydrated

Specialty: Internal Medicine, Hematology & Oncology

Practice Location: DOWNEY, CA 90241

NPI Number: 1801046867

LIFETIME INDUSTRY VALUE

$157

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BOONCHALERMVICHIAN is a verified Internal Medicine, Hematology & Oncology practitioner based in DOWNEY, CA.

Between 2021 and 2025, Dr. BOONCHALERMVICHIAN had an overall industry promotional and research financial footprint of $157 as recorded in the federal CMS Open Payments database.

$157 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BOONCHALERMVICHIAN's primary funding source is KITE PHARMA, which accounts for $118 (representing 74.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

KITE PHARMA

Rank 1

$118

74.9%

BAYER HEALTHCARE PHARMACEUTICALS

Rank 2

$23

14.6%

CUMBERLAND PHARMACEUTICALS

Rank 3

$16

10.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.